$Instil Bio (TIL.US)$ not boucing as expected not strong technical and fundamental to hold  overtime done here realizing less then 10% loss

$Instil Bio (TIL.US)$ back in my shooting range pre breakout level entry zone missed that time now becoming support lets see goal is sell equal or above 50% gain or stopping loss below 20%
Support and Resistance Levels
There is defined support just below $28, which aligns with recent consolidation days at around 20 days, giving some expectation of long-term support. Resistance can potentially be found at recent highs close to $27.70, which coincides with key psychological barriers and past rapid ...

$Instil Bio (TIL.US)$ 👀missed past breakout entry now re-testing mode can it make to top? tons of resistances upside…..

$Instil Bio (TIL.US)$
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
Tuesday, 14th January at 7:00 am
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China
ImmuneOnco announced initial clinical data from the 1L advanced NSCLC trial in China is expected as early as 2H 2025
Instil is target...

$Instil Bio (TIL.US)$  is it a buy ?

$Immuneering (IMRX.US)$ $2.9-3.5
keep  👀 $Instil Bio (TIL.US)$

Shares of $Instil Bio (TIL.US)$surged over 60% on Friday after Baird raised its price target to $180, signaling a potential 146% upside. Despite this rally, retail investors remain cautious.
Baird's optimism is driven by promising developments in Instil’s PD-L1xVEGF bispecific antibody, especially following positive data from peers like Akeso and Summit. Analysts believe this drug class has strong potentia...

$Instil Bio (TIL.US)$ god i wish there were put options for this thing lol